Johnson & Johnson’s Experience Navigating The Commissioner’s National Priority Voucher Program
Johnson & Johnson’s hematology division secured FDA approval for a new multiple myeloma regimen—Tecvayli plus Darzalex Faspro—through the FDA Commissioner’s National Priority Voucher pilot. The approval came just 55 days after filing, marking the first blood‑cancer therapy to use the voucher pathway. The combination leverages a BCMA‑targeting bispecific antibody and a CD38 monoclonal antibody to deliver synergistic efficacy without traditional IMiDs or proteasome inhibitors. Johnson & Johnson also instituted IVIG prophylaxis and coordinated dosing to mitigate infection risk.
Pharma Finance Roundup: Platform Innovation Drives Biotech Investment Across Oncology and Immunology
This week’s biotech financing spotlighted platform‑driven innovation in oncology and immunology. Adcendo closed a $75 million Series C to expand its ADC pipeline, while Beeline Medicines launched with $300 million Series A to develop precision autoimmune therapies. Harbinger Health secured $100 million for its multi‑cancer...
A New Standard for Copay Excellence: Q&A with Brian Laird
Pharmaceutical manufacturers are confronting escalating out‑of‑pocket costs, high‑deductible plans and fragmented payer rules, prompting a shift from static copay reimbursements to strategic, data‑driven solutions. EVERSANA, which already processes over 12 million claims for 1.5 million patients, launched its Intelligent Copay Solution to...
How Are Regulatory Factors Impacting Biosimilars
The FDA issued draft guidance in March that would drop certain pharmacokinetic (PK) studies for biosimilars, aiming to lower development costs. At the same time, the Inflation Reduction Act (IRA) and most‑favored‑nation (MFN) pricing provisions are reshaping how manufacturers price...
Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement
AbbVie signed an exclusive licensing deal with China’s Haisco Pharmaceutical to develop, manufacture and sell a suite of novel pain compounds outside mainland China, Hong Kong and Macau. The agreement provides Haisco $30 million upfront and up to $715 million in milestone payments,...
How Serious Is the Biosimilar Void?
The FDA released a draft guidance in March 2026 that would drop certain pharmacokinetic (PK) studies, easing biosimilar development and cutting costs. Samsung Bioepis SVP Thomas Newcomer says a biosimilar void still exists in the U.S., especially for mid‑volume and...
Building Operational Visibility in Clinical Trials: Q&A with Deepak Prakash
Identiv VP Deepak Prakash explains how RFID and Bluetooth‑enabled tracking is reshaping clinical trial operations by delivering continuous, real‑time visibility of assets, samples, and shipments. The technology replaces fragmented, manual data entry with automated condition monitoring, cutting reconciliation costs and...
Implications of Tecvayli Plus Darzalex Faspro Demonstrating 83% Reduction in Disease Progression or Death.
Johnson & Johnson’s Tecvayli (teclistamab) combined with Darzalex Faspro (daratumumab) achieved an 83% reduction in disease progression or death in a Phase III trial for relapsed/refractory multiple myeloma. The study, presented at ASH, reported a hazard ratio of 0.17, higher response rates,...
Pharmaceutical Executive Daily: FDA Issues Second CRL for Replimune's RP1 Melanoma Treatment
The FDA issued a second complete response letter rejecting Replimune’s biologics license application for RP1 combined with nivolumab in advanced melanoma, citing insufficient data to isolate RP1’s contribution. Replimune’s CEO warned of job cuts and a scale‑back of U.S. manufacturing....
Managing Patient Experience and RWE in Clinical Trials: Q&A with Matt Holms, MB
Recent enrollment shortfalls in Pfizer/BioNTech COVID‑19 and Lyme vaccine studies underscore how operational flaws can derail promising drugs. Matt Holms, VP of commercial, patient engagement and recruitment at Citeline, explains that modern trial design must integrate real‑world data, AI‑driven patient...
Pharmaceutical Executive Daily: Shionogi Receives Contract Through BARDA's Project BioShield
Shionogi’s U.S. subsidiary secured a BARDA Project BioShield contract that could total $482 million to develop and manufacture its gram‑negative antibiotic Fetroja, with an initial $119 million funded. The agreement funds a U.S. production facility and expands research against high‑priority biothreat pathogens...
How Does the Complexity of Obesity Impact the Effectiveness of GLP-1s?
The FDA granted accelerated approval for a high‑dose injectable version of Wegovy, while Novo Nordisk introduced a multi‑month subscription model aimed at telehealth prescribers. New data from Phenomix and the Mayo Clinic reveal that many patients lack a clear understanding...
Pharmaceutical Executive Daily: Shah Capital's Plan to Vote Against Novavax Board Nominees
Shah Capital, Novavax's second‑largest shareholder with about 9% ownership, announced it will vote against the re‑election of all board nominees and the company's executive compensation proposals at the upcoming annual meeting. In a letter, the activist fund demanded a 30%...
Q&A: Supply Chain Fallout From Iran War, Tariff Uncertainty
The Iran war has disrupted airspace and closed the Strait of Hormuz, driving up fuel surcharges and forcing pharma shipments onto longer, costlier routes. Simultaneously, the Supreme Court ruled that the president lacks authority to impose blanket tariffs under IEEPA,...
Why Advisory Committees Remain Essential in an Era of Complex Medicines
A senior FDA official recently dismissed advisory committees as costly, slow, and theatrical, prompting renewed debate over their role in drug review. Advisory committees (AdComs) are independent panels that convene when a therapy presents a nuanced benefit‑risk profile, offering real‑time...
